Low-sodium oxybate reduces 24-hour sleep duration and daytime napping in adults with idiopathic hypersomnia, according to a phase 3 trial analysis.

“Waking up in the morning is very, very hard. I don’t hear alarms, smell smoke, or feel water. There are very few things that can wake me up, and it’s also very hard for the person who wakes me up. On ...

Avadel Pharmaceuticals announced that its drug LUMRYZTM received Orphan Drug Designation from the FDA for treating Idiopathic Hypersomnia (IH), a rare sleep disorder. This designation, based on the ...

Zevra is a corporate sponsor of the Hypersomnia Foundation and Beyond Sleepy Conference CELEBRATION, Fla., June 03, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the ...

SEATTLE -- Low-sodium oxybate (Xywav) reduced blood pressure as expected compared with the higher-sodium version (Xyrem), reduced nocturnal arousal, and appeared safe at doses above 9 g, a series of ...

Xywav is the only FDA-approved treatment studied across the multiple symptoms of idiopathic hypersomnia, such as EDS, sleep inertia (severe grogginess or confusion when waking up), long sleep duration ...

DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZ TM has been ...

Harmony Biosciences was seeking FDA approval to expand its label for Wakix to include idiopathic hypersomnia. Shares of Harmony Biosciences dropped Wednesday after the Food and Drug Administration ...